We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Diabetes Drug Warning.
- Authors
Mitka, Mike
- Abstract
This article reports on the decision of the U.S. Food and Drug Administration (FDA) to request "black box" warnings on the drugs rosiglitzone and pioglitazone which are used to lower blood glucose levels in diabetic patients. The request for warnings was announced by FDA Commissioner Andrew C. von Eschenbach during testimony at a Congressional House hearing. The warning does not mention the risk for myocardial infarction although studies are suggesting that the drug may increase the risk of heart failure.
- Subjects
UNITED States; UNITED States. Food &; Drug Administration; WARNING labels; DRUG side effects; TREATMENT of diabetes; VON Eschenbach, Andrew C., 1941-; MYOCARDIAL infarction risk factors; CONGRESSIONAL hearings (U.S.)
- Publication
JAMA: Journal of the American Medical Association, 2007, Vol 298, Issue 2, p166
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.298.2.166-a